E.W. Scripps Co. Cl A (SSP) Financials Nov 17, 2014, 4:23

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
E.W. Scripps Co. Cl A (SSP) Financials Nov 17, 2014, 4:23 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for E.W. Scripps Co. Cl A


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 802.36M 776.89M 728.66M 903.46M 816.87M
Cost of Goods Sold (COGS) incl. D&A 794.2M 731.42M 730.44M 612.62M 612.14M
COGS excluding D&A 749.03M 686.52M 690.37M 563.29M 564.38M
Depreciation & Amortization Expense 45.17M 44.89M 40.07M 49.33M 47.76M
Depreciation 43.34M 43.52M 38.82M 42.26M 40.84M
Amortization of Intangibles 1.83M 1.38M 1.25M 7.07M 6.92M
Gross Income 8.16M 45.47M (1.78M) 290.84M 204.73M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - - - 74.7M 55.19M
Research & Development - - 0 0 0
Other SG&A - - - 74.7M 55.19M
Other Operating Expense 0 0 0 126.6M 130.85M
Unusual Expense 226.35M 12.68M 21.72M 15.16M 9.49M
EBIT after Unusual Expense (226.35M) (12.68M) (21.72M) (15.16M) (9.49M)
Non Operating Income/Expense (229,000) 580,000 (551,000) (5.22M) (6.68M)
Non-Operating Interest Income 0 0 0 0 0
Equity in Affiliates (Pretax) 1.75M 0 0 - -
Interest Expense 2.55M 3.67M 1.64M 12.25M 11.1M
Gross Interest Expense 2.55M 3.67M 1.64M 12.25M 11.1M
Interest Capitalized 0 0 0 - -
Pretax Income (219.23M) 29.71M (25.69M) 56.91M (8.57M)
Income Tax (27.17M) 840,000 (10M) 16.99M (7.85M)
Income Tax - Current Domestic (65.64M) (38.74M) (26.73M) (2.98M) (2.78M)
Income Tax - Current Foreign 1.49M 0 0 - -
Income Tax - Deferred Domestic 65.57M 31.68M 19.75M 19.97M (5.07M)
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 28.6M (7.9M) 3.02M - -
Equity in Affiliates - - 0 - -
Other After Tax Income (Expense) - (14.6M) - (1.85M) 0
Consolidated Net Income (192.06M) 14.27M (15.69M) 38.08M (724,000)
Minority Interest Expense (42,000) (103,000) (150,000) (266,000) (250,000)
Net Income (192.01M) 14.37M (15.54M) 38.34M (474,000)
Extraordinaries & Discontinued Operations (17.59M) 101.54M 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (17.59M) 101.54M 0 0 0
Net Income After Extraordinaries (209.61M) 115.91M (15.54M) 38.34M (474,000)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (192.01M) 14.37M (15.54M) 38.34M (474,000)
EPS (Basic) (3.89) 2.04 (0.27) 0.70 (0.01)
Basic Shares Outstanding 53.9M 56.86M 57.22M 54.91M 56.52M
EPS (Diluted) (3.89) 2.03 (0.27) 0.69 (0.01)
Diluted Shares Outstanding 53.9M 57M 57.22M 55.38M 56.52M
EBITDA 53.33M 90.37M 38.29M 138.87M 66.46M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Russel Metals Shows Strong Performance in Latest Earnings Report

Updated Category News Views 240

Russel Metals Inc. Reports Third Quarter Results for 2025 Russel Metals Inc. (TSX:RUS) has recently shared its financial performance for the three-month period ending September 30, 2025. The results reflect a positive trajectory in revenue and strategic initiatives to enhance its market position. Key Financial Metrics Overview In this quarter, Russel Metals has...

Continue Reading
KBC Group Shows Strong Capital Resilience Ahead of Changes

Updated Category News Views 257

KBC Group's Capital Position Remains Strong KBC Group has reported a robust standing in its capital levels, significantly exceeding the minimum capital requirements mandated by the European Central Bank (ECB). As part of the Supervisory Review and Evaluation Process (SREP) scheduled for the upcoming year, KBC received formal notification regarding its capital metrics....

Continue Reading
Synlogic's Q3 Financial Update Highlights Strategic Review

Updated Category News Views 79

Synlogic Provides Third Quarter 2024 Financial Results Synlogic, Inc. (NASDAQ: SYBX), a prominent biopharmaceutical firm dedicated to developing innovative therapeutics for serious diseases, has recently outlined its financial performance for the third quarter of 2024. The organization is actively working on advancing its mission to enhance healthcare through...

Continue Reading
Incannex Healthcare Sees Growth with Positive Fiscal Results

Updated Category News Views 98

Incannex Healthcare's Remarkable Financial Progress Incannex Healthcare Inc. (NASDAQ: IXHL) is making impressive strides in the biopharmaceutical world, focusing on breakthrough treatments for chronic diseases. Their recent fiscal year report outlines not only financial outcomes but also a plethora of operational and clinical advancements aimed at addressing significant...

Continue Reading
Revolutionizing Finance with ChatAnalyst at Alpha Liquid Terminal

Updated Category News Views 167

Alpha Liquid Terminal Introduces ChatAnalyst Financial Agent Recently, a game-changing tool was launched that promises to redefine how individuals manage and interpret financial data. This is powered by the innovative company, Alpha Liquid Terminal. The newly unveiled AI-driven financial analyst agent, known as ChatAnalyst, is designed to simplify and streamline financial...

Continue Reading